Rucaparib (AG-014699,PF-01367338) phosphate

Catalog No.S1098

Rucaparib (AG-014699,PF-01367338) phosphate Chemical Structure

Molecular Weight(MW): 421.36

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 57 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
Features The first PARP inhibitor used in clinical trials combined with temozolomide.
Targets
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
In vitro

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 NUD3eHZSTnWwY4Tpc44hSXO|YYm= NV\wSHJ1OC5zL{GvOVAxNzFyMECgcm0> NWD4SGFJcW6qaXLpeJMhWEGUUDDhZ5Rqfmm2eTDheEB{fGG{dHnu[{Bkd26lZYLueJJifGmxbjDv[kA2ODBibl2= M372S|I2OTJ6NEW1
BT474 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:1NFAhdk1? MlPCNVDjiJNzNdMg[C=> MoDWdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> M3faW|I2OTJ6NEW1
SKBR3 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:1NFAhdk1? NWnKZXhPOTEkgKOxOeKh\A>? M{L4WJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> MX2yOVEzQDR3NR?=
AU565 NH\Obm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu1NFAhdk1? NH;Ib5oyOOLCk{G1xsBl M{G3TJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> M{nVe|I2OTJ6NEW1
EFM192A NWLPdZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTDclk2ODBibl2= NVjOTFFJOTEkgKOxOeKh\A>? NIq0V|Vz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6 NEf2NnMzPTF{OES1OS=>
MDA-MB-231 MkjMSpVv[3Srb36gRZN{[Xl? M{jkNFExNzJyL{SwJO69VQ>? MljvNlQhcA>? MXfpcoNz\WG|ZYOgdE1CU1RibHX2[Yx{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NILROHQzPDR{MEG1Ni=>
MDA-MB-231 NETsblVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXnyO4hCOC5zLUSwJO69VQ>? Mn6wNlQhcA>? MX3JR|Ux6oDLPfMAjVE4Njd5wrFOwG0> M33OOVI1PDJyMUWy
MDA-MB-231 MoXrRZBweHSxc3nzJGF{e2G7 NW[yZlB3OTBxMkCvOFAh|ryP M1X2[lI1KGh? MkLEbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MnXYNlQ1OjBzNUK=
MDA-MB-231 NHO3WoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrzNVAwOjBxNECg{txO NXOyeFNVOjRiaB?= MUjicI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvckBqdiCJMj;NJJBp[XOn Mk\qNlQ1OjBzNUK=
H460 NXPDNYk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\vOFAxKG6P NUDL[3FrOjUEoHi= NX\y[JVKcW6lcnXhd4V{KGOnbHz1cIFzKHKjZHnvd4Vve2m2aY\peJk> NWLpT4pOOjR2MUG2NVE>
A549  MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVO0NFAhdk1? M1TB[FI1yqCq NIfQblJqdmO{ZXHz[ZMh[2WubIXsZZIhemGmaX;z[Y5{cXSrdnn0fS=> NFS1RY4zPDRzMU[xNS=>
DT40 NVH2dVNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnCRodKSzVyPUKxJI5O NVjueXFKOjR|NU[4NVM>
DU145 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF6IH7N NV7OT4xIOjR|NU[4NVM>
COLO704 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPjc5E5UUN3ME2yMlUzKMLzIECuOlch|ryP NIjBSlAzOzd{OUSwNi=>
OVMANAb NWTO[2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfjc5pKSzVyPUKuOVghyrFiMD6zPEDPxE1? Mm\uNlM4Ojl2MEK=
OV177 NYHMNG83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFexeYNKSzVyPUKuO|ghyrFiMD63NUDPxE1? M{XGflI{PzJ7NECy
OAW28 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXGTWM2OD1|Lk[xJOKyKDBwMkig{txO NFzkXnYzOzd{OUSwNi=>
OVSAHO Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwNkSgxtEhOC5|MzFOwG0> NVjrN3RrOjN5Mkm0NFI>
OVKATE MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjPXWdKSzVyPUOuOlQhyrFiMT63PUDPxE1? M3PSbVI{PzJ7NECy
OVCAR3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTNwN{SgxtEhOC52MDFOwG0> M3zFPFI{PzJ7NECy
PEO14 NGD2SldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:3VoU2UUN3ME2zMlg1KMLzIECuO|Yh|ryP MXSyN|czQTRyMh?=
A2780 NUnRb3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLxTWM2OD1|Lkm0JOKyKDBwMkWg{txO NYHVfW1DOjN5Mkm0NFI>
OVTOKO NFvkTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7DTWM2OD12LkG0JOKyKDFwNUOg{txO MofSNlM4Ojl2MEK=
KURAMOCHIb NUDwT2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTRwM{SgxtEhOC5{OTFOwG0> MXeyN|czQTRyMh?=
TOV21G NVfmfZZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILBcY1KSzVyPUWuNFchyrFiMT6zNEDPxE1? NUXnNJYxOjN5Mkm0NFI>
OVISE NHG5[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDFNnVjUUN3ME21MlY5KMLzIECuNlMh|ryP NY\NNYRXOjN5Mkm0NFI>
KK Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvSUmRxUUN3ME22MlE2KMLzIEGuOFIh|ryP M4i0NVI{PzJ7NECy
RMUGS Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfFTWM2OD15LkCzJOKyKDFwOEOg{txO Mm\oNlM4Ojl2MEK=
PEO6 NHvKV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTdwME[gxtEhOC55NDFOwG0> MlnuNlM4Ojl2MEK=
OVCA429 NX7uOZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnHTWM2OD16LkK5JOKyKDFwNkSg{txO M{DOWlI{PzJ7NECy
OV167 NWTqe|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImxOmlKSzVyPUiuN|MhyrFiMT6xPEDPxE1? NF\vVZQzOzd{OUSwNi=>
RMG1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjD[pVKSzVyPUmuN|IhyrFiMj6zOkDPxE1? NYTVbVVNOjN5Mkm0NFI>
OVCAR5 NGrPVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[0SJN2UUN3ME25MlUxKMLzIEKuOVkh|ryP MV2yN|czQTRyMh?=
EFO21 M2\xcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXZ[GdKSzVyPUmuPVIhyrFiMT64O{DPxE1? MUOyN|czQTRyMh?=
ES2 NUnmXnBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTHfFdKSzVyPUGwMlEzKMLzIEGuNlMh|ryP NIPNSY8zOzd{OUSwNi=>
Tyk-nu NUnEXHpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFyLkKwJOKyKDFwMUKg{txO MYCyN|czQTRyMh?=
CAOV3 M1;qS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3npeWlEPTB;MUCuN|chyrFiMD64O{DPxE1? NVf5e4Q{OjN5Mkm0NFI>
OV207 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7qTWM2OD1zMj6yO{DDuSByLkOyJO69VQ>? M3zTelI{PzJ7NECy
HEY NXTEWHNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf2TWM2OD1zMz6wNUDDuSByLke1JO69VQ>? MmfBNlM4Ojl2MEK=
DOV13 M3fQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;MdGlEPTB-MUWg{txO MlfDNlM4Ojl2MEK=
EFO27 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRjF3IN88US=> MWOyN|czQTRyMh?=
HEY C2 NHTBVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TWdGlEPTB-MUWg{txO M1mydVI{PzJ7NECy
KOC-7cc MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[0VY1KSzVyPkG1JO69VQ>? NX62N2NNOjN5Mkm0NFI>
MCASb MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRjF3IN88US=> MmTCNlM4Ojl2MEK=
OAW42 NH;1eYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly0TWM2OD5zNTFOwG0> Ml7BNlM4Ojl2MEK=
OV2008 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGwTnNKSzVyPkG1JO69VQ>? NH:3[pczOzd{OUSwNi=>
OV90 Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nv[2lEPTB-MUWg{txO Mo\XNlM4Ojl2MEK=
OVCA420b MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:wXnhKSzVyPkG1JO69VQ>? NIXZPWMzOzd{OUSwNi=>
OVCA432 NG\DTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTVTWM2OD5zNTFOwG0> NYT6bXA4OjN5Mkm0NFI>
PEA2 M4TBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRjF3IN88US=> M4GxOFI{PzJ7NECy
SKOV3 NV7tSlRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfSTWM2OD5zNTFOwG0> M{iwO|I{PzJ7NECy
TOV112D MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7OeGExNTNizszN NGC1foVKSzVyPkG1JO69VQ>? MUKyN|czQTRyMh?=
C4-2 NUXURoxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLXNE0{KM7:TR?= NHvDZ4syPCCm NVnVbmNiTE2VTx?= Mkf2[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? M1npb|I{PTZ3MkS0
PC3 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOwMVMh|ryP M{fx[FE1KGR? M3nrfGROW09? MoHv[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MVSyN|U3PTJ2NB?=
DU145 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\VWWdmOC1|IN88US=> NFjZXnkyPCCm MYXEUXNQ NVLm[IlH\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= M2P1c|I{PTZ3MkS0
VCaP  MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnYVlExNTNizszN M{XDUFE1KGR? MoXzSG1UVw>? M3nJXIRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? NIL2[mozOzV4NUK0OC=>
LNCaP  NGHS[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLYTmwxNTNizszN M1uwNVE1KGR? NWjwemtITE2VTx?= M1HRS4Rm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? M3XHV|I{PTZ3MkS0
MDA-MB-468 NXG0XlNyS2WubDDWbYFjcWyrdImgRZN{[Xl? NFHNco1KSzVyPUmuO{DPxE1? NVO4Tnc6OjJ4N{ixOlE>
MDA-MB-231 NYLqVYpZS2WubDDWbYFjcWyrdImgRZN{[Xl? MlzCTWM2OD1zMzFOwG0> NGqwdJYzOjZ5OEG2NS=>
Cal-51 MoXjR4VtdCCYaXHibYxqfHliQYPzZZk> NWq5PJNPUUN3ME24MlYh|ryP MUOyNlY4QDF4MR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PAR; 

PubMed: 27960087     


MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.

BRCA1; 

PubMed: 24085845     


MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. 

27960087 24085845
Growth inhibition assay
Cell viability; 

PubMed: 31119062     


The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

31119062
Immunofluorescence
α-tubulin; 

PubMed: 30589644     


Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. 

PAR; 

PubMed: 27515310     


Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown.

γH2AX; 

PubMed: 23565244     


γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 

53BP1; 

PubMed: 23565244     


53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.

30589644 27515310 23565244
In vivo Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

Protocol

Kinase Assay:[1]
- Collapse

Ki Determination:

Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
Cell Research:[4]
- Collapse
  • Cell lines: D425Med, D283Med and D384Med cells
  • Concentrations: 0.4 μM
  • Incubation Time: 3 or 5 days
  • Method: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: CD-1 nude mice bearing established D283Med xenografts
  • Formulation: Normal saline
  • Dosages: 1 mg/kg
  • Administration: One or four daily by i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.36
Formula

C19H18FN3O.H3PO4

CAS No. 459868-92-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03954366 Recruiting Drug: Rucaparib|Drug: Rosuvastatin|Drug: Oral Contraceptives Neoplasms Clovis Oncology Inc. May 8 2019 Phase 1
NCT03824704 Recruiting Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine May 15 2019 Phase 2
NCT03413995 Recruiting Drug: Rucaparib Prostate Cancer Metastatic Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Clovis Oncology Inc. September 10 2018 Phase 2
NCT03572478 Recruiting Drug: Rucaparib|Drug: Nivolumab Prostate Cancer|Endometrial Cancer University of Chicago|Bristol-Myers Squibb|Clovis Oncology Inc. August 14 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate supplier | purchase Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate cost | Rucaparib (AG-014699,PF-01367338) phosphate manufacturer | order Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID